drugset
drugset / Trial / NCT00436852

ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment

NCT00436852 ↗

Phase 2 Completed 92 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well ABT-751 works in treating children with neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Timeline

Start
2007-01
Primary completion
2010-09-01
Completion
2015-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-751 Other / unclassified 200 mg/m2 Oral

Indications

neuroblastoma